Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 12,349

Document Document Title
WO/2012/125991A3
The invention describes compositions that include a stevia sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and/or lingering of the s...  
WO/2012/119846A1
The present invention relates to synthetic lipoteicoic acid (LTA) mimeticswhich are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.  
WO/2012/121394A1
The present invention provides a substituted aromatic compound represented by general formula (I) [wherein A1, A2 and A3 independently represent an aryl group substituted by a hydrophilic group].  
WO/2012/121862A2
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/122282A1
A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impu...  
WO/2012/121862A3
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/116447A1
A combination of a bacterial endotoxin, in particular a lipopolysaccharide, and a lipoteichoic acid for treating or preventing a metabolic disorder or bacterial infection, or for improving milk energy efficiency in a subject. The combina...  
WO/2012/113405A1
A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the m...  
WO/2012/107204A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetness enhancer, to sweetener compositions comprising at least one sweetener and the compoun...  
WO/2012/107205A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising the compound of for...  
WO/2012/104145A1
The present invention relates to an improved process for the preparation of an extract enriched in dihydrochalcones, and more specifically enriched in phlorizin, starting from a polyphenolic fraction originating from industrial apple pro...  
WO/2012/101605A1
The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R...  
WO/2012/097876A1
A novel class of cell-penetrating enhancers with unusual chemical structure is herein disclosed. Said cell-penetrating enhancers are non-linear and non peptidic (guanidyl)-oligosaccharidic derivatives, which can be easily obtained accord...  
WO/2012/099477A1
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...  
WO/2012/097454A1
This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof: wherein R1 to R4. R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said c...  
WO/2012/099904A1
The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive a...  
WO/2012/095793A3
The present invention comprises compounds of formula (I) and (II), embodying a 3-enopyranoside-2-ulose system and compound of formula (III), presenting a pyranoside α,β,γ,δ-unsaturated ester skeleton, derived from compound of formula...  
WO/2012/094752A1
A process for producing a natural sweetening enhancer composition comprising at least an Rebaudioside C (RC) extract, said process comprises the steps of preparing a saccharide mother liquor comprising an RC mass content of at least 15%;...  
WO/2012/096884A1
Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.  
WO/2012/093091A2
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...  
WO/2012/094540A2
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...  
WO/2012/093091A3
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...  
WO/2012/094540A3
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of a-galactosyl ceramides, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...  
WO/2012/091570A1
A carbohydrate-containing feedstock is converted in a process, which process comprises contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100 °C to yield an intermedi...  
WO/2012/088598A1
A process for producing the natural sweetener composition which comprises at least one of steviolbioside (STB) extract, Rebaudioside B extract and Rebaudioside D extract ("collectively, the "extracts") comprises the steps of preparing a ...  
WO/2012/088612A1
A method for breeding Stevia rebaudiana with a high content of RA comprises selecting the plants in the perfect stage with a high RA content as parents and hybridizing them to produce F1 generation seeds; stabilizing the traits of the F1...  
WO/2012/088593A1
Natural steviol glycosides sweetener compositions comprise a blend of Rebaudioside C extract and at least one of Rebaudioside A extract and STV extract including methods for producing the same and uses thereof in foods, beverages, functi...  
WO/2012/085668A3
The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The sacch...  
WO/2012/088264A2
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...  
WO/2012/086811A1
The present invention provides a food intake suppressant and an anti-obesity agent containing the compounds represented by formula (I''). (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O- group (where G represents a s...  
WO/2012/088264A3
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...  
WO/2012/086812A1
The present invention provides the compounds represented by formula (I''), a method for producing the compounds, and GLP-1 secretagogues etc. containing the compounds. (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O-...  
WO/2012/082677A1
Sweetener compositions comprising particular glycoside blends are described in this paper. The glycioside blends comprise rebaudioside A, rebaudioside B, and/or rebaudioside D in various proportions. The sweetener composition can also in...  
WO/2012/082587A3
The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Stevia rebaudiana Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are ...  
WO/2012/082493A1
A process for production of crystalline rebaudioside B from rebaudioside A is described. Additionally, four distinct crystal polymorphic forms of rebaudioside B are described, as well as methods for converting from one crystal polymorphi...  
WO/2012/082650A3
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...  
WO/2012/082650A2
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...  
WO/2012/079039A1
A preparation of antibiotic G418 with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic G418 with a purity of greater than 95% and no individual group ...  
WO/2012/073214A3
Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.  
WO/2012/073214A4
Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.  
WO/2012/073214A2
Compounds having the general formula (I) and their biological applications.  
WO/2012/071371A2
The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microa...  
WO/2012/071371A3
The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microa...  
WO/2012/069730A1
The invention relates to a compound having Formula (I), nC7-H15-O-(G)p-H (I), where G is the residue of a reducing sugar, and p is a decimal number greater than or equal to 1.05 and less than or equal to 5. The invention also relates to ...  
WO/2012/071508A1
A method of preparing a ribofuranose derivative essentially free of pyranose compounds includes a step of contacting a solution of MDR containing MDRP as an impurity in a solvent including methanol and/or tetrahydrofuran with at least on...  
WO/2012/066949A1
Radish is a plant highly valuable as a food material. The purpose of the present invention is to provide a glucoraphanin-rich radish plant at a low cost using neither a chemical treatment nor a transgenic treatment, said glucoraphanin ha...  
WO/2012/068457A1
The invention relates to the use of adsorb/desorb chromatography to prepare enriched compositions comprising rebaudioside B and/or rebaudioside D. Compositions with enriched rebaudioside-B and/or rebaudioside-D components may be prepared...  
WO/2012/067978A1
Compounds having antibacterial activity are disclosed. The compounds have a structure including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with prepa...  
WO/2012/062996A1
The invention relates to compounds of formula (I) where: R1 ≠ 2-deoxystreptamine and the derivatives thereof substituted in positions 5 and/or 6; R2 and R6 are the same or different and represent a primary, secondary or tertiary amine ...  
WO/2012/065054A1
A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula I: A-B wherein A comprises a carbohydrate that is a neuraminidase or galactosidase substrate; B comprises an odorant moiety; B is co...  

Matches 351 - 400 out of 12,349